4//SEC Filing
Paya Carlos V 4
Accession 0001209191-23-054846
CIK 0001649094other
Filed
Nov 8, 7:00 PM ET
Accepted
Nov 9, 4:36 PM ET
Size
21.9 KB
Accession
0001209191-23-054846
Insider Transaction Report
Form 4
Vaxcyte, Inc.PCVX
Paya Carlos V
Director
Transactions
- Gift
Stock Option (right to buy)
2023-11-09−15,000→ 0 totalExercise: $53.08Exp: 2033-06-12→ Common Stock (15,000 underlying) - Gift
Common Stock
2023-11-09−3,125→ 2,500 total - Gift
Stock Option (right to buy)
2023-11-09−30,000→ 0 totalExercise: $22.02Exp: 2031-10-26→ Common Stock (30,000 underlying) - Gift
Stock Option (right to buy)
2023-11-09−18,750→ 0 totalExercise: $22.70Exp: 2032-05-31→ Common Stock (18,750 underlying) - Award
Common Stock
2023-11-09+3,125→ 3,125 total(indirect: By Trust) - Gift
Stock Option (right to buy)
2023-11-09+30,000→ 30,000 total(indirect: By Trust)Exercise: $22.02Exp: 2031-10-26→ Common Stock (30,000 underlying) - Gift
Stock Option (right to buy)
2023-11-09+18,750→ 18,750 total(indirect: By Trust)Exercise: $22.70Exp: 2032-05-31→ Common Stock (18,750 underlying) - Gift
Stock Option (right to buy)
2023-11-09+15,000→ 15,000 total(indirect: By Trust)Exercise: $53.08Exp: 2033-06-12→ Common Stock (15,000 underlying)
Footnotes (7)
- [F1]The reported transactions involve the Reporting Person's transfer of certain securities to a trust for the sole benefit of the Reporting Person.
- [F2]As previously disclosed in Reporting Person's Form 4 filed on June 15, 2023, this represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
- [F3]Shares are held directly by a trust for the sole benefit of the Reporting Person.
- [F4]Option vests over 36 months, 1/3 of which will vest on October 27, 2022 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.
- [F5]Options are held directly by a trust for the sole benefit of the Reporting Person.
- [F6]The shares of Common Stock subject to the option vested fully on June 1, 2023.
- [F7]The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Documents
Issuer
Vaxcyte, Inc.
CIK 0001649094
Entity typeother
Related Parties
1- filerCIK 0001606244
Filing Metadata
- Form type
- 4
- Filed
- Nov 8, 7:00 PM ET
- Accepted
- Nov 9, 4:36 PM ET
- Size
- 21.9 KB